A U.S. biotech company is opting for an initial public offering in Hong Kong, bypassing Wall Street. This move highlights a growing trend among global biotech firms attracted to Hong Kong's expanding investor pool and proximity to the Chinese pharmaceutical market.
US Biotech Firm Chooses Hong Kong for Initial Listing Amid Growing Investor Base
IPObiotechnologyHong_Kongcapital_marketslisting_strategy
